Cargando…
(18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study
BACKGROUND: Positron emission tomography/computed tomography (PET/CT) using radiotracers that bind to the prostate-specific membrane antigen (PSMA) is mainly used in biochemical recurring prostate cancer. The aim of our study was to assess the usefulness of (18)F-JK-PSMA-7 PET/CT for local and nodal...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868215/ https://www.ncbi.nlm.nih.gov/pubmed/36683076 http://dx.doi.org/10.1186/s41824-022-00161-2 |
_version_ | 1784876483264643072 |
---|---|
author | Vierasu, Irina Van Simaeys, Gaetan Trotta, Nicola Lacroix, Simon Bormans, Guy Albisinni, Simone Quackels, Thierry Roumeguère, Thierry Goldman, Serge |
author_facet | Vierasu, Irina Van Simaeys, Gaetan Trotta, Nicola Lacroix, Simon Bormans, Guy Albisinni, Simone Quackels, Thierry Roumeguère, Thierry Goldman, Serge |
author_sort | Vierasu, Irina |
collection | PubMed |
description | BACKGROUND: Positron emission tomography/computed tomography (PET/CT) using radiotracers that bind to the prostate-specific membrane antigen (PSMA) is mainly used in biochemical recurring prostate cancer. The aim of our study was to assess the usefulness of (18)F-JK-PSMA-7 PET/CT for local and nodal staging in patients with intermediate- and high-risk prostate cancer (PCa) prior to radical prostatectomy, as compared to conventional imaging techniques. METHODS: We enrolled a total of 10 patients with intermediate- and high-risk PCa diagnosed by multiparametric-MRI followed by systematic and targeted biopsies, eligible for radical prostatectomy with extended lymph node dissection. Clinical team was blind to the results of the pre-surgery (18)F-JK-PSMA-7 PET/CT at times of clinical decision and surgery. One month post-surgery, 18F-JK-PSMA-7 PET/CT was repeated and the results of both scans were unblinded. A third (18)F-JK-PSMA-7 PET/CT could be acquired at a later time point depending on PSA progression. RESULTS: All pre-surgery (18)F-JK-PSMA-7 PET/CT was positive in the prostatic region, while MRI was negative in the prostate in one patient. We also detected positive pelvic lymph nodes in two patients (one high-risk, one intermediate-risk PCa) on pre-surgery and post-surgery (18)F-JK-PSMA-7 PET/CT. No positive pelvic lymph nodes were reported on pre-surgical CT and MRI. (18)F-JK-PSMA-7 PET/CT detected bladder involvement in one patient and seminal vesicles involvement in two patients; this malignant extension was undetected by the conventional imaging techniques. SUVmax in prostate lesions had an average value of 11.51 (range 6.90–21.49). SUVmean in prostate lesions had an average value of 7.59 (range 5.26–14.02). CONCLUSION: This pilot study indicates that pre-surgery (18)F-JK-PSMA-7 PET/CT provides valuable information in intermediate- and high-risk PCa, for surgery planning with curative intent. |
format | Online Article Text |
id | pubmed-9868215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-98682152023-01-24 (18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study Vierasu, Irina Van Simaeys, Gaetan Trotta, Nicola Lacroix, Simon Bormans, Guy Albisinni, Simone Quackels, Thierry Roumeguère, Thierry Goldman, Serge Eur J Hybrid Imaging Original Article BACKGROUND: Positron emission tomography/computed tomography (PET/CT) using radiotracers that bind to the prostate-specific membrane antigen (PSMA) is mainly used in biochemical recurring prostate cancer. The aim of our study was to assess the usefulness of (18)F-JK-PSMA-7 PET/CT for local and nodal staging in patients with intermediate- and high-risk prostate cancer (PCa) prior to radical prostatectomy, as compared to conventional imaging techniques. METHODS: We enrolled a total of 10 patients with intermediate- and high-risk PCa diagnosed by multiparametric-MRI followed by systematic and targeted biopsies, eligible for radical prostatectomy with extended lymph node dissection. Clinical team was blind to the results of the pre-surgery (18)F-JK-PSMA-7 PET/CT at times of clinical decision and surgery. One month post-surgery, 18F-JK-PSMA-7 PET/CT was repeated and the results of both scans were unblinded. A third (18)F-JK-PSMA-7 PET/CT could be acquired at a later time point depending on PSA progression. RESULTS: All pre-surgery (18)F-JK-PSMA-7 PET/CT was positive in the prostatic region, while MRI was negative in the prostate in one patient. We also detected positive pelvic lymph nodes in two patients (one high-risk, one intermediate-risk PCa) on pre-surgery and post-surgery (18)F-JK-PSMA-7 PET/CT. No positive pelvic lymph nodes were reported on pre-surgical CT and MRI. (18)F-JK-PSMA-7 PET/CT detected bladder involvement in one patient and seminal vesicles involvement in two patients; this malignant extension was undetected by the conventional imaging techniques. SUVmax in prostate lesions had an average value of 11.51 (range 6.90–21.49). SUVmean in prostate lesions had an average value of 7.59 (range 5.26–14.02). CONCLUSION: This pilot study indicates that pre-surgery (18)F-JK-PSMA-7 PET/CT provides valuable information in intermediate- and high-risk PCa, for surgery planning with curative intent. Springer International Publishing 2023-01-23 /pmc/articles/PMC9868215/ /pubmed/36683076 http://dx.doi.org/10.1186/s41824-022-00161-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Vierasu, Irina Van Simaeys, Gaetan Trotta, Nicola Lacroix, Simon Bormans, Guy Albisinni, Simone Quackels, Thierry Roumeguère, Thierry Goldman, Serge (18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study |
title | (18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study |
title_full | (18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study |
title_fullStr | (18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study |
title_full_unstemmed | (18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study |
title_short | (18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study |
title_sort | (18)f-jk-psma-7 pet/ct for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868215/ https://www.ncbi.nlm.nih.gov/pubmed/36683076 http://dx.doi.org/10.1186/s41824-022-00161-2 |
work_keys_str_mv | AT vierasuirina 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy AT vansimaeysgaetan 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy AT trottanicola 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy AT lacroixsimon 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy AT bormansguy 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy AT albisinnisimone 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy AT quackelsthierry 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy AT roumeguerethierry 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy AT goldmanserge 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy |